144977 20260218132342.0 doi 10.3390/cancers16162798 sideral 139840 ART-2024-139840 eng Sesma, Andrea Peripheral Blood TCRß Repertoire, IL15, IL2 and Soluble Ligands for NKG2D Activating Receptor Predict Efficacy of Immune Checkpoint Inhibitors in Lung Cancer 2024 Access copy available to the general public Unrestricted The development of immune checkpoint inhibitors (ICIs) has changed the therapeutic paradigm of lung cancer (LC), becoming the standard of treatment for previously untreated advanced non-small cell lung cancer (NSCLC) without actionable mutations. It has allowed the achievement of durable responses and resulted in significant survival benefits. However, not all patients respond; hence, molecular biomarkers are needed to help us predict which patients will respond. With this objective, a prospective observational study was designed, including a cohort of 55 patients with NSCLC who received ICIs. We studied whether biomarkers such as TCRβ and specific cytokines involved in the regulation of T cell activity were related to the immunotherapy response. In the survival analysis, it was found that patients with higher TCRβ clonality, lower TCRβ evenness, higher TCRβ Shannon diversity and lower TCRβ convergence had higher overall survival (OS) and progression-free survival (PFS). However, no statistically significant association was observed. Regarding cytokines, those patients with higher levels of IL-2 and IL-15 presented statistically significantly shorter OS and PFS, respectively. In fact, in the multivariable analysis, the high IL-15 level increased the risk of death by three times. Although the sample size was small and more studies are needed to confirm our results, our study reveals promising markers of responses to ICIs. info:eu-repo/grantAgreement/ES/AEI/PID2020-113963RB-I00 info:eu-repo/grantAgreement/ES/AEI/PTA2019-016739-I info:eu-repo/grantAgreement/ES/AEI/RYC2022-036627-I info:eu-repo/grantAgreement/ES/DGA/B29-20R info:eu-repo/semantics/openAccess by https://creativecommons.org/licenses/by/4.0/deed.es 4.4 2024 ONCOLOGY 85 / 328 = 0.259 2024 Q2 T1 1.462 2024 Oncology 2024 Q1 Cancer Research 2024 Q2 8.8 2024 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Pardo, Julian Universidad de Zaragoza (orcid)0000-0003-0154-0730 Isla, Dolores M. Gálvez, Eva Gascón-Ruiz, Marta Universidad de Zaragoza (orcid)0000-0002-6811-6654 Martínez-Lostao, Luis Universidad de Zaragoza (orcid)0000-0003-3043-147X Moratiel, Alba Paño-Pardo, J. Ramón Universidad de Zaragoza (orcid)0000-0002-9600-8116 Quílez, Elisa Torres-Ramón, Irene (orcid)0000-0003-3387-0558 Yubero, Alfonso Zapata-García, María Domingo, María Pilar Esteban, Patricia Sanz Pamplona, Rebeca Lastra, Rodrigo Ramírez-Labrada, Ariel (orcid)0000-0002-3888-7036 1011 566 Universidad de Zaragoza Dpto. Microb.Ped.Radio.Sal.Pú. Área Inmunología 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 16, 16 (2024), 2798 [22 pp.] Cancers Cancers 2072-6694 2160429 http://zaguan.unizar.es/record/144977/files/texto_completo.pdf Versión publicada 2889652 http://zaguan.unizar.es/record/144977/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:144977 articulos driver 2026-02-18-12:27:27 ARTICLE